Directive 75/318/EEC
Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products. This directive of the European Union sought to bring the benefits of innovative pharmaceuticals to patients across Europe by introducing the mutual recognition, by Member States, of their respective national marketing authorisations.
The Directive states that Member States shall take all appropriate measures to ensure that the applications for marketing authorization, are submitted by the applicants in accordance with the guidelines of the Directive.
See also
- EudraLex
- Directive 75/319/EEC
- Directive 65/65/EEC1
- Directive 93/41/EEC
- Directive 2001/83/EC
- Regulation of therapeutic goods
- European Medicines Agency
References
This article is issued from Wikipedia - version of the 1/29/2013. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.